1 year return (CAGR)
-7.00%
Idorsia Ltd Exchange (SW, CHF)
IDIA.SW
4.05
-0.29 (-6.60%)
HealthcareBiotechnology
Loading...
3 year return (CAGR)
16.07%
5 year return (CAGR)
-28.61%
10 year return (CAGR)
-
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
1.09B
Price/Sales
5.45
Ent value
2.66B
Price/Book
-
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
0.00%
Trailing P/E
-
PEG
-
Forward P/E
73.24
EPS growth
-30.05%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 4.28 |
| Daily high | 4.28 |
| Daily low | 4.05 |
| Daily Volume | 1.36M |
| All-time high | 33.62 |
| 1y analyst estimate | 5.33 |
| Beta | 1.64 |
| EPS (TTM) | -1.24 |
| Dividend per share | 0.00 |
| Ex-div date | 16 Jun 2017 |
| Next earnings date | 26 Feb 2026 |
Downside potential
Loading...
Downside potential data
| IDIA.SW | S&P500 | |
| Current price drop from All-time high | -87.95% | -0.66% |
| Highest price drop | -98.12% | -56.47% |
| Date of highest drop | 20 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -52.77% | -10.67% |
| Avg time to new high | 62 days | 12 days |
| Max time to new high | 1689 days | 1805 days |
News
Idorsia (SWX:IDIA) continues to attract attention after recent share price moves, with the stock down 4.5% on the latest trading day and showing weaker performance over the past month and the past thr...
September 25, 2026
Idorsia has given investors a wild ride over the past few years, and the big question now is whether the current share price can be squared with the revenue the business is generating. With the stock ...
September 24, 2026
Ad hoc announcement pursuant to Art. 53 LR The DEA states that dual orexin receptor antagonists “do not produce physical or psychological dependence”Lower schedule expected to enhance patient access i...
August 11, 2026
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant) sales reached CHF 91 million in H1 2026, up 62% year-on-year. Full-year 2026 guidance reaffirmed. Company focused on four key drivers...
July 30, 2026
Idorsia will publish its Half Year 2026 Financial Reporting on Thursday July 30, at 07:00 CEST. An investor webcast and conference call will be held to discuss the results on the same day. Date: Thurs...
July 23, 2026
Ad hoc announcement pursuant to Art. 53 LR Idorsia appoints Roland Wandeler as CEO – effective October 1, 2026 – an experienced biopharmaceutical executive combining scientific expertise with business...
July 1, 2026
If you are wondering whether Idorsia at CHF4.39 is still interesting after a strong run, the next sections will focus on what the current price might mean for value oriented investors. The stock has p...
June 2, 2026
High-dose cohort confirms the favorable safety profile and the dose-dependent immune response against Clostridioides difficile bacteria and spores Allschwil, Switzerland – June 1, 2026Idorsia Ltd (SIX...
June 1, 2026
The findings demonstrate that aprocitentan may help reduce the risk of kidney disease progression, cardiovascular events, and mortality in patients with resistant hypertension. Allschwil, Switzerland ...
June 1, 2026
Allschwil, Switzerland – May 6, 2026At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Boar...
May 6, 2026